Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hill expands ephedra investigation

This article was originally published in The Tan Sheet

Executive Summary

Former Yellow Jackets manufacturer NVE Pharmaceuticals is latest firm to receive House Energy & Commerce Committee letter as part of its ongoing ephedra investigation. Correspondence, sent April 21, asks NVE President Robert Occhifinto to disclose information on its marketing practices and AEs related to sale of Yellow Jackets. Committee also recently expanded its inquiry to include PediaLean children's weight-loss supplement (1"The Tan Sheet" April 14, 2003, p. 4). Yellow Jackets and NVE were the subject of an FDA investigation and concurrent Senate subcommittee hearing in October 2002 (2"The Tan Sheet" Oct. 14, 2002, p. 6). Firm has until May 5 to respond...

You may also be interested in...

Steroid Precursor Legislative Action Gains Momentum

"Pro-steroid" and "precursor steroid" products' proliferation in the dietary supplement market "raise[s] questions about whether additional federal action should be taken," according to the House Energy & Commerce Committee

NVE Pharmaceuticals N.J. Plant Stung In FDA Yellow Jacket Investigation

FDA is in the process of inspecting NVE Pharmaceuticals' Newton, N.J. plant, where Yellow Jacket ephedra/caffeine supplements are manufactured

Singulair’s Psychiatric AE Risks Still A Problem, But US FDA Has Limited Mitigation Options Remaining

Stakeholders suggested a ‘Dear Healthcare Provider’ letter or speaking about the risks to professional societies to emphasize the psychiatric adverse events that prompted a boxed warning for the now-generic asthma drug montelukast. The NY Attorney General is adding more pressure.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts